Takachiho Co., Ltd. logo

Takachiho Co., Ltd. (8225)

Market Closed
2 Oct, 06:00 AM
JPX JPX
¥
3,650. 00
-45
-1.2179%
¥
- Market Cap
- P/E Ratio
- Div Yield
500 Volume
- Eps
¥ 3,695
Previous Close
Add Transaction
Day Range
3,650 3,700
Year Range
3,160 4,480
Want to track 8225 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

8225 closed Friday lower at ¥3,650, a decrease of -1.2179% from Thursday's close, completing a monthly decrease of -1.2179% or -¥45. Over the past 12 months, 8225 stock lost -1.3514%.
8225 is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Takachiho Co., Ltd. has completed 1 stock splits, with the recent split occurring on Sep 27, 2017.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

8225 Chart

Takachiho Co., Ltd. (8225) FAQ

What is the stock price today?

The current price is ¥3,650.00.

On which exchange is it traded?

Takachiho Co., Ltd. is listed on JPX.

What is its stock symbol?

The ticker symbol is 8225.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Takachiho Co., Ltd. ever had a stock split?

Takachiho Co., Ltd. had 1 splits and the recent split was on Sep 27, 2017.

Takachiho Co., Ltd. Profile

Professional Services Industry
Industrials Sector
- CEO
JPX Exchange
JP3457700007 ISIN
China Country
41 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

China Health Group Inc., initially established under the name Venturepharm Laboratories Limited in 1998, is a prominent investment holding company based in Beijing, China. After a strategic rebranding in January 2015, it adopted the current name to more accurately reflect its broadened scope in the healthcare industry. The company is dedicated to offering a wide range of clinical research services primarily to pharmaceutical and biotechnology companies located within the People's Republic of China. Its services are pivotal in assisting these entities through various phases of drug development and post-launch market activities, enhancing the effectiveness and reach of medical treatments across the country.

Products and Services

  • Contracted Clinical Research Services
  • This service involves conducting comprehensive clinical trials and studies to ensure the safety and efficacy of new pharmaceutical products. China Health Group Inc. leverages its expertise and infrastructure to manage various phases of clinical research, facilitating the development process for its clients.

  • Contracted Pharmaceutical Development Services
  • These services cater to the needs of pharmaceutical firms aiming to bring new drugs to the market. From formulation development to regulatory submission support, the company provides end-to-end solutions that streamline the journey of a drug from the laboratory to the pharmacy shelf.

  • Post Launch Market Research, Medical, and Medical Market Services
  • Understanding the market dynamics post-launch is crucial for the success of any medical product. China Health Group Inc. offers comprehensive market research, medical marketing, and other support services to help clients navigate the challenges after launching their products, ensuring sustained success and compliance with market needs.

  • Hospital Management, Medical Tourism, and Specialized Hospital Services
  • Expanding its portfolio beyond pharmaceutical services, China Health Group Inc. delves into hospital management and medical tourism. These services are aimed at improving hospital operational efficiencies and attracting patients globally for specialized treatments, thereby enhancing healthcare standards and accessibility.

  • Venturepharma Cloud
  • A digital platform facilitating seamless cooperation between China Health Group Inc., its partners, and clients. This cloud-based solution is designed to streamline communication, data management, and project tracking, thereby optimizing the pharmaceutical development process.

  • Drug Technologies Sales
  • In addition to services, the company also engages in the sales of drug technologies. This includes licensing and distribution of proprietary medicinal solutions, enabling the commercialization of innovative treatments and contributing to the advancement of healthcare technologies.

Contact Information

Address: Building 17
Phone: 86 21 6115 8121